Comparative Pharmacology
Head-to-head clinical analysis: METHYLIN versus METHYLIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLIN versus METHYLIN ER.
METHYLIN vs METHYLIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylphenidate is a central nervous system stimulant. It blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Methylphenidate is a central nervous system stimulant that blocks the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their availability in the synaptic cleft.
10 mg orally twice daily, administered 4-6 hours apart; doses may be adjusted in 5-10 mg increments weekly up to 60 mg/day.
20-60 mg orally once daily in the morning
None Documented
None Documented
2-4 hours (short elimination half-life, requiring multiple daily dosing; immediate-release: 3-4 hours, extended-release: 3-6 hours)
Mean 3-6 hours in adults; longer in children (4-8 hours). Clinical context: steady-state reached within 2 days; dosing every 8-12 hours.
Renal: 90% (mainly as metabolites, 30-50% as unchanged drug); fecal: <1%
Renal (90% as metabolites, <1% unchanged). Biliary/fecal: <2%.
Category C
Category C
CNS Stimulant
CNS Stimulant